Novartis' Atrasentan (Noruida®) Becomes First High-Selectivity Endothelin A (ETA) Receptor Antagonist Approved in China for IgA Nephropathy
Novartis
Drug Development and Manufacturing
Note:This article does not constitute any investment opinions or recommendations., subject to official/company announcements;This article only introduces drugs related to medical health, not a recommendation of treatment options (if involved), and does not represent the platform's position.Any article reprinted needs to be authorized.
Novartis China President and Managing Director Li Yao said, "We are very pleased to usher in the field of kidney disease treatment.Another ProductApproved in China. This is the first non-immunological basic treatment for the disease in China, offering a new therapeutic option for patients with IgA nephropathy. This approval will also benefit a wider patient population. This year, Novartis has had two products successively approved in the field of kidney disease treatment, fully demonstrating our firm commitment to accelerating the introduction of innovative drugs and achieving synchronization with the rest of the world. In the future, Novartis will continue to leverage its profound accumulation of over 40 years in the field of kidney disease treatment, advance the innovation pipeline layout in this field more quickly, and provide patients with more precise, effective, and safer treatment options.
2025 will be a year of great changes and transformations. On the one hand, affected by changes in the domestic and international environment, competition in the clinical trial industry has become more intense. Whether to cut costs for survival or transform for breakthroughs is a major challenge faced by every clinical research supplier. On the other hand, advancements in new technologies such as AI and updates to ICH GCP have driven innovation in clinical trial concepts and technological transformation, presenting new opportunities and challenges for the clinical trial industry and specialized suppliers.
Against the backdrop of major policy, market, and technological changes and adjustments in the clinical trial industry,The 2nd China Clinical Trial Industry Development Conference Will Be Held in Nanjing on October 23-24, 2025, we will adopt a mindset of starting from scratch, fully redesign, and deeply integrate industry, academia, research, government, and capital to build a collaborative ecosystem platform for the clinical trial industry that serves clinical research suppliers and promotes high-quality development in the clinical trial sector.
At this conference, we will summarize the 40-year history of China's clinical trial industry, and release the annual China Clinical Trial Industry Report and the Professional Staff Survey Report. We will also present the Annual Excellence in Clinical Research Supplier Award, the Excellence in Clinical Research Professional Award, and the Industry Historical Figure Tribute Award. We look forward to your anticipation, support, and participation!
↓↓Scan the code to register now↓↓
2025CCTI，
Our efforts will focus on:
Meeting Time:October 23-24, 2025
Hosted by:Clinical Research Professionals, Pharmaceutical Circle
Meeting Location:Nanjing
Participants:
1. Pharmaceutical and Medical Device R&D and Manufacturing Enterprises
2. Clinical CRO/SMO
3. Clinical Trial Parties and Supplier Enterprises (Systems, AuditsSearch, PharmaceuticalsSupply, BioassayTest, PV, translation, etc.)
1. A 40-Year Report on Clinical Trials in China
2. Award Ceremony for Outstanding Contributors to 40 Years of Clinical Trials in China
3. 2025 Clinical Trial Industry Development Survey Report
4. 2025 Annual Excellence in Clinical Research Supplier Awards
5. 2025 Clinical Research Professionals Employment Status Survey Report
6. 2025 Annual Excellence in Clinical Research Awards
· New Trends and Clinical Trial Development
1. Latest Policies on Innovative Drug Research, Development and Commercialization
2. Latest Developments and Trends in International Pharmaceutical Regulation
3. Jiangsu Province Policies to Promote the Development of the Biopharmaceutical Industry and Clinical Trials
4. New Trends in the Development of the Biomedical Industry Abroad
5. Going Global and International Innovation: Overseas Expansion and Phase III Clinical Development Strategies for Innovative Drugs
6. NEWCOAuthorized Transactions
· New Technologies and Clinical Trial Transformation
1. AIEmpower Clinical Trials
2. DCTPractice and Application
3. Digital Management of Clinical Trial Institutions
4. Remote Intelligent Clinical Trial Operations Practice
5. Informatization Management of Clinical Trials
6. Integrated Management System for Clinical Trials
· New Regulations and Clinical Trial Management
1. Interpretation of the Latest Policies on Clinical Trial Management
2. Latest Verification Standards and Trends
3. FDA/EMAInspection Standards and Common Issues
4. Construction of Institutional Quality Management System
5. Safety Event Verification Standards and Quality Management
6. Challenges and Responses in Clinical Trial Quality Management Brought by New Technologies
· Clinical Trials of Innovative Drugs
1. ADC
2. RDC
3. Gene and Cell Therapy
4. Nucleic Acid Drugs and Delivery Technologies
5. Peptide Drugs
6. Innovative Traditional Chinese Medicine/Natural Medicines
· Modified New Drug/Generic Drug Clinical Trials
1. Clinical Value and Development Strategies of Modified New Drugs
2. Development Opportunities and Challenges for Modified New Drug Clinical Trials
3. Challenges and Reflections in Clinical Research of Complex Formulations
4. Development Challenges and Application of New Technologies in Modified Compound Formulations
5. Development and Clinical Trials of Transdermal Preparations
6. Design and Analysis of Clinical Trials for Bioequivalence Evaluation
· Medical Device/IVDRegistration and Clinical Trials
1. Current Status and Trends in Innovative Device Registration
2. Medical Device Export and International Registration
3. IVDInnovation in R&D and Clinical Trials
4. Clinical Trials of Orthopedic Innovative Devices
5. Clinical Trials of Surgical Robots
6. AIEmpower Device R&D and Clinical Trials
· Clinical Trial Medical Affairs and Statistics
1. Medical Strategy
2. Medical Monitoring
3. Pharmacovigilance
4. Medical Writing
5. Data Management
6. Statistical Analysis
· Clinical Trial Supply Chain and Central Laboratory Management
1. Pharmaceutical Supply Chain Management
2. Central Laboratory
3. Biological Sample Management
4. Equipment Rental
5. Logistics and Warehousing
6. Digitalization andAIEmpower Supply Chain Management
· Clinical Research and Achievement Transformation in Medical Institutions
1. Construction and Management of Biobanks
2. Investigator-Initiated Study Management
3. Hospital Diagnosis and Treatment Database Applied in Clinical Research
4. Application of Hospital Diagnostic Databases in Drug Development
5. Compliance and Ethical Issues in Clinical Research and Technology Transfer in Medical Institutions
6. Analysis of Medical Institution Achievement Transformation Examples
Rooted in Shanghai and radiating globally, PharmaCircle serves as a strategic platform for the biopharmaceutical industry with the mission of "enabling the borderless flow of intelligence and networks." It has established an empowerment system covering the entire pharmaceutical industry chain, including R&D, production, distribution, and commercialization. Through four core engines—intelligent cloud services, precise resource connections, industry think tanks, and ecosystem communities—it builds the infrastructure for the flow of pharmaceutical value in China.
Under the dual waves of globalization and digitalization, PharmaCircle is redefining the circulation paradigm of pharmaceutical resources — it is not only a hub for information and networking but also a catalyst for industrial transformation. With China as the origin, we are weaving a global network of pharmaceutical intelligence, making every precise connection a catalyst for enterprises’ leapfrog growth.
